Compare
Definium Therapeutics, Inc. vs USANA Health Sciences Inc vs Cronos Group Inc. vs Natural Alternatives International Inc
| Latest fiscal year | Definium Therapeutics, Inc. DFTX | USANA Health Sciences Inc USNA | Cronos Group Inc. CRON | Natural Alternatives International Inc NAII |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-01-03 | 2025-12-31 | 2025-06-30 |
| Revenue | n/a | $925.26M | $146.59M | $129.86M |
| Revenue growth (YoY) | n/a | +8.3% | +24.6% | +14.1% |
| Gross margin | n/a | 78.3% | 42.8% | 7.2% |
| Operating margin | n/a | 4.0% | -11.9% | -6.7% |
| Net margin | n/a | 1.2% | -6.4% | -10.5% |
| Net income | -$183.79M | $10.76M | -$9.45M | -$13.57M |
| EPS (Diluted) | -$2.06 | $0.58 | -$0.02 | -$2.28 |
| Operating cash flow | -$131.56M | $22.35M | $25.87M | $5.93M |
| Free cash flow | n/a | $8.53M | $149.0K | $2.32M |
| Cash & equivalents | $257.84M | $158.38M | $791.79M | $12.32M |
| Total assets | $440.10M | $742.91M | $1.20B | $151.94M |
| Total liabilities | $107.77M | $156.64M | $54.18M | $83.51M |
| Shareholders' equity | $332.33M | $533.10M | $1.14B | $68.43M |
| Return on year-end equity | -55.3% | 2.0% | -0.8% | -19.8% |
| Shares outstanding | 98.78M | 18.28M | 381.59M | 6.18M |
Revenue, most recent five fiscal years
| Fiscal year | Definium Therapeutics, Inc. | USANA Health Sciences Inc | Cronos Group Inc. | Natural Alternatives International Inc |
|---|---|---|---|---|
| Latest | n/a | $925.26M Ended 2026-01-03 | $146.59M Ended 2025-12-31 | $129.86M Ended 2025-06-30 |
| 1 year earlier | n/a | $854.50M Ended 2024-12-28 | $117.61M Ended 2024-12-31 | $113.80M Ended 2024-06-30 |
| 2 years earlier | n/a | $921.01M Ended 2023-12-30 | $87.24M Ended 2023-12-31 | $154.01M Ended 2023-06-30 |
| 3 years earlier | n/a | $998.60M Ended 2022-12-31 | $86.75M Ended 2022-12-31 | $170.97M Ended 2022-06-30 |
| 4 years earlier | n/a | $1.19B Ended 2022-01-01 | $64.56M Ended 2021-12-31 | $178.52M Ended 2021-06-30 |